CDSCO approves Astellas' PADCEV for First-Line Advanced Bladder Cancer Treatment

May 21, 2026

Mumbai (Maharashtra) [India], May 21: Astellas Pharma India today announced that PADCEV™ (enfortumab vedotin) in combination with pembrolizumab is now approved for the first-line...